tetano
Editor, Senior Moderator
Kobe J Med Sci
. 2025 Feb 3;70(4):E106-E112.
doi: 10.24546/0100492945. Epidemiology of SARS-CoV-2 Infection in Patients with Neuromuscular Disease and Inborn Errors of Metabolism: A Cross-sectional Study for a Pediatric Outpatient Referral in Japan
Sungwon Hong[SUP] 1 [/SUP], Kiiko Iketani[SUP] 2 [/SUP], Shoko Sonehara[SUP] 1 [/SUP], Hiroaki Hanafusa[SUP] 1 [/SUP], Yoshinori Nambu[SUP] 1 [/SUP], Kandai Nozu[SUP] 1 [/SUP], Hiroyuki Awano[SUP] 1 3 [/SUP], Ryosuke Bo[SUP] 1 [/SUP]
Affiliations
The coronavirus disease 2019 (COVID-19) pandemic has affected people worldwide, and pediatric patients with underlying diseases are at high risk of developing severe COVID-19. However, there are limited reports on the clinical impact of COVID-19, especially in patients with underlying neuromuscular diseases (NMD) and inborn errors of metabolism (IEM). This study aimed to investigate the incidence and clinical presentation of COVID-19 in patients with NMD and IEM. This was a single-center, cross-sectional study of patients with NMD and IEM in Japan for 2 years, from April 1, 2020 to March 31, 2022. Among 255 participants with a median age of 14 (range: 0-50) years, 192 (75%) and 63 (25%) had NMD and IEM, respectively. Among 255 patients, 8 (5 NMD and 3 IEM) were positive for the anti-severe acute respiratory syndrome coronavirus 2 nucleocapsid antibody, and the incidence was considered 3%. All positive patients had mild or asymptomatic COVID-19. None of the patients exhibited moderate or severe symptoms. In conclusion, this study revealed that the incidence of COVID-19 was low, and mild or subclinical infection was common even in patients with NMD and IEM, who may be at a higher risk of severe COVID-19.
Keywords: Inborn errors of metabolism; COVID-19; Neuromuscular diseases; Pediatric.
. 2025 Feb 3;70(4):E106-E112.
doi: 10.24546/0100492945. Epidemiology of SARS-CoV-2 Infection in Patients with Neuromuscular Disease and Inborn Errors of Metabolism: A Cross-sectional Study for a Pediatric Outpatient Referral in Japan
Sungwon Hong[SUP] 1 [/SUP], Kiiko Iketani[SUP] 2 [/SUP], Shoko Sonehara[SUP] 1 [/SUP], Hiroaki Hanafusa[SUP] 1 [/SUP], Yoshinori Nambu[SUP] 1 [/SUP], Kandai Nozu[SUP] 1 [/SUP], Hiroyuki Awano[SUP] 1 3 [/SUP], Ryosuke Bo[SUP] 1 [/SUP]
Affiliations
- PMID: 39993783
- DOI: 10.24546/0100492945
The coronavirus disease 2019 (COVID-19) pandemic has affected people worldwide, and pediatric patients with underlying diseases are at high risk of developing severe COVID-19. However, there are limited reports on the clinical impact of COVID-19, especially in patients with underlying neuromuscular diseases (NMD) and inborn errors of metabolism (IEM). This study aimed to investigate the incidence and clinical presentation of COVID-19 in patients with NMD and IEM. This was a single-center, cross-sectional study of patients with NMD and IEM in Japan for 2 years, from April 1, 2020 to March 31, 2022. Among 255 participants with a median age of 14 (range: 0-50) years, 192 (75%) and 63 (25%) had NMD and IEM, respectively. Among 255 patients, 8 (5 NMD and 3 IEM) were positive for the anti-severe acute respiratory syndrome coronavirus 2 nucleocapsid antibody, and the incidence was considered 3%. All positive patients had mild or asymptomatic COVID-19. None of the patients exhibited moderate or severe symptoms. In conclusion, this study revealed that the incidence of COVID-19 was low, and mild or subclinical infection was common even in patients with NMD and IEM, who may be at a higher risk of severe COVID-19.
Keywords: Inborn errors of metabolism; COVID-19; Neuromuscular diseases; Pediatric.